Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.59 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7689616 | 0.87 | NR1H3 (0.71) | NR1H3NR1H2MEN1KMT2AALDH1A1 | |
| SCHEMBL6676139 | 0.84 | MEN1 (0.68) | NR1H3NR1H2MEN1KMT2AGRM1 | |
| SCHEMBL6679321 | 0.84 | KMT2A (0.54) | NR1H3NR1H2MEN1KMT2ASCN2A | |
| SCHEMBL11808285 | 0.84 | ESR1 (0.72) | NR1H3NR1H2MEN1KMT2ASCN2A | |
| SCHEMBL10915309 | 0.83 | CYP3A4 (0.60) | NR1H3NR1H2MEN1KMT2ASCN2A | |
| SCHEMBL7733937 | 0.82 | HTR3A (0.56) | NR1H3NR1H2 | |
| SCHEMBL30758650 | 0.81 | KMT2A (0.76) | NR1H3NR1H2MEN1KMT2ASCN2A | |
| SCHEMBL29168849 | 0.81 | KMT2A (0.76) | NR1H3NR1H2MEN1KMT2ASCN2A | |
| SCHEMBL4256269 | 0.80 | NR1H3 (0.52) | NR1H3NR1H2MEN1KMT2AGRM1 | |
| SCHEMBL2578102 | 0.80 | NR1H3 (0.52) | NR1H3NR1H2MEN1KMT2AGRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181288-B1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | UPJOHN CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN | 2002-10-03 | — | — | US | disclosed |
| US-6387896-B1 | GRAMNEGATIVE, GRAMPOSITVE BACTERIA | PHARMACIA & UPJOHN CO. | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | OXA1L, MRPL21, RPS4Y1 | G6PD 534/4885TLR9 1497/4885NR1H3 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.